Q-omics provides the consensus-scored BNIP5 profile across patient tissues and cancer cell-line models. BNIP5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, BNIP5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, BNIP5 RNA expression shows 12,340 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BRCA, COAD, and ESCA as cancer lineages where BNIP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP5 survival associations across molecular data types. BNIP5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP5 RNA expression–survival associations across cancer types. High BNIP5 expression shows unfavorable associations in KIRC, THCA and ACC, but favorable associations in BRCA, CESC and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for BNIP5 RNA expression.
This table summarizes BNIP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for BNIP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP5 shows higher tumor expression in COAD, LUAD, BRCA, THCA, STAD and HNSC. The COAD box plot shows higher BNIP5 RNA expression in tumor versus normal tissue (log2 FC = +1.503, t-test p < 0.001).
This table shows molecular features associated with BNIP5 in patient tissues and cancer cell lines. In patient samples, BNIP5 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, BNIP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
